AllAnalyst Report
Morningstar•December 09, 2021
Morningstar•December 09, 2021Edwards Lifesciences Corporation: Despite Pandemic Disruptions, Edward Lifesciences' Narrow Moat Remains Strong; Raising Our FVE
Summary
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Analyst Report: Abbott LaboratoriesApr 17, 2024 •
ABT
- RMD: Lowering target price to $194.00Apr 17, 2024 •
RMD
- ALGN: Lowering target price to $320.00Apr 17, 2024 •
ALGN
- IDXX: Lowering target price to $514.00Apr 17, 2024 •
IDXX
- TRUP: Lowering target price to $18.00Apr 17, 2024 •
TRUP, DXCM
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.